XML 30 R19.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information
13. SEGMENT INFORMATION

Information regarding industry segments at March 31, 2026 and 2025 and for the three months then ended are as follows (in millions):
Life
Science		Clinical
Diagnostics
Net sales2026$228.5 $363.6 
 2025$228.6 $356.8 
Cost of goods sold
2026$100.9 $181.8 
2025$100.2 $179.2 
Segment gross profit2026$127.6 $181.8 
 2025$128.4 $177.6 
Depreciation and amortization
2026$18.3 $22.6 
2025$17.0 $21.1 
Segment assets
2026$301.7 $468.8 
2025$308.1 $482.0 

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The segment measure of profit and loss used by our chief operating decision maker ("CODM") is Gross Profit, which represents Net sales reduced by Cost of goods sold, and is the primary measure used by the CODM to evaluate segment performance and allocate resources.
The following reconciles total segment gross profit to net income (loss) before income taxes (in millions):
Three Months Ended
March 31,
 20262025
Segment gross profit$309.4 $306.0 
Selling, general and administrative expense
(212.4)(208.8)
Research and development expense
(62.9)(73.5)
Interest expense(12.3)(12.0)
Foreign currency exchange gains, net2.4 2.7 
Gains (losses) from change in fair market value of equity securities and loan receivable(738.2)31.8 
Other income, net24.2 37.2 
Net income (loss) before income taxes$(689.8)$83.4